Magenta Therapeutics, Inc.
MGTA · NASDAQ
12/31/2024 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $6,235 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 0% | – | – | – |
| R&D Expenses | $83,105 | $55,141 | $46,766 | $50,615 |
| G&A Expenses | $24,994 | $25,761 | $27,926 | $28,087 |
| SG&A Expenses | $24,994 | $25,761 | $27,926 | $28,087 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $108,099 | $80,902 | $74,692 | $78,702 |
| Operating Income | -$101,864 | -$80,902 | -$74,692 | -$78,702 |
| % Margin | -1,633.7% | – | – | – |
| Other Income/Exp. Net | $16,895 | $4,440 | $3,556 | $3,766 |
| Pre-Tax Income | -$84,969 | -$76,462 | -$71,136 | -$74,936 |
| Tax Expense | $0 | -$4,440 | -$5,576 | -$5,744 |
| Net Income | -$84,969 | -$72,022 | -$65,560 | -$69,192 |
| % Margin | -1,362.8% | – | – | – |
| EPS | -21.75 | -23.05 | -1.12 | -1.43 |
| % Growth | 5.6% | -1,958% | 21.7% | – |
| EPS Diluted | -21.75 | -23.05 | -1.12 | -1.43 |
| Weighted Avg Shares Out | 3,907 | 3,125 | 58,793 | 48,460 |
| Weighted Avg Shares Out Dil | 3,907 | 3,125 | 58,793 | 48,460 |
| Supplemental Information | – | – | – | – |
| Interest Income | $17,365 | $0 | $3,556 | $3,766 |
| Interest Expense | $0 | -$4,440 | $0 | $0 |
| Depreciation & Amortization | $0 | $1,925 | $2,020 | $1,978 |
| EBITDA | -$101,864 | -$78,977 | -$74,692 | -$78,702 |
| % Margin | -1,633.7% | – | – | – |